CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
LAIV H5N2 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01719783
NCT01719783Phase 1Completed
CompareCT.gov

Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Turkey/Turkey/05/133 (H5N2) Influenza Vaccine

PATH·interventional·Posted Nov 1, 2012·Updated Nov 28, 2018

In Brief

A Phase 1 clinical trial evaluating LAIV H5N2 and Placebo for Influenza. Completed, enrolled 40 participants across 1 site.

Detailed Summary

To evaluate the safety profile of two intranasal doses of LAIV A/17/turkey/Turkey/05/133 (H5N2) in healthy adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesRussia
CollaboratorsMicrogen, Institute of Experimental Medicine, Russia

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 1, 2012
Enrollment StartSep 1, 2012
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.7 years ago

Interventions

LAIV H5N2biological

2 doses provided intranasally

Placeboother

2 doses of placebo provided intranasally